Drug trial success boosts Vectura
Vectura, the pharma company specialising in treatments for respiratory diseases, says a trial of one of its development drugs has shown better results than the main competitor.
Vectura, the pharma company specialising in treatments for respiratory diseases, says a trial of one of its development drugs has shown better results than the main competitor.
The not-catchily titled QVA149 is a treatment delivered through an inhaler, mainly targeted at chronic obstructive pulmonary disease - a condition often seen in smokers, or people working in a polluted environment, which can cause debilitating bouts of breathlessness.
The latest study results show a once daily dose of QVA149 gives patients "superior" lung function to the twice daily treatment Seretide.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The drug will now progress to phase III trials in the US, managed by its partner in the project, pharma giant, Novartis.
Vectura shares had gained 4.35% by 10:12.
BS
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
UK property market forecast: where are house prices heading?
House prices have climbed in the past few years, but the long-term outlook for the housing market is poor, says Max King
By Max King Published
-
Next-generation dividend heroes: the top-yielding investment trusts of the future?
The Association of Investment Companies has published its updated list of next-gen dividend heroes. We look at the trusts that made the cut
By Dan McEvoy Published